22.87
0.37 (1.64%)
| Previous Close | 22.50 |
| Open | 22.65 |
| Volume | 270,662 |
| Avg. Volume (3M) | 258,111 |
| Market Cap | 1,117,409,920 |
| Price / Book | 3.90 |
| 52 Weeks Range | |
| Earnings Date | 12 Mar 2025 - 17 Mar 2025 |
| Diluted EPS (TTM) | -1.89 |
| Total Debt/Equity (MRQ) | 0.05% |
| Current Ratio (MRQ) | 17.44 |
| Operating Cash Flow (TTM) | -72.17 M |
| Levered Free Cash Flow (TTM) | -31.10 M |
| Return on Assets (TTM) | -21.37% |
| Return on Equity (TTM) | -30.98% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Enliven Therapeutics, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | 2.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -0.5 |
| Average | 0.50 |
|
Enliven Therapeutics Inc is a clinical-stage precision oncology company focused on the discovery and development of potentially first-in-class precision oncology therapies. Enliven’s programs are designed to address issues such as tolerability, combinability, resistance and disease escape through brain metastases. Its product candidates include ELVN-001 which is a potent, selective, small molecule kinase inhibitor designed to specifically target the BCR-ABL gene fusion, the oncogenic driver for patients with chronic myeloid leukemia, and the ELVN-002 which is central nervous system (CNS) penetrant and irreversible HER2 inhibitor with activity against wild type HER2 and various HER2 mutations. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 6.39% |
| % Held by Institutions | 98.86% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Vr Adviser, Llc | 30 Sep 2024 | 4,026,331 |
| Fairmount Funds Management Llc | 30 Sep 2024 | 3,202,798 |
| 5Am Venture Management, Llc | 30 Sep 2024 | 1,752,174 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 42.00 (BTIG, 83.65%) | Buy |
| Median | 38.50 (68.34%) | |
| Low | 36.00 (Jones Trading, 57.41%) | Buy |
| Average | 38.75 (69.44%) | |
| Total | 4 Buy | |
| Avg. Price @ Call | 25.35 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| BTIG | 13 Dec 2024 | 42.00 (83.65%) | Buy | 23.15 |
| Baird | 15 Nov 2024 | 40.00 (74.90%) | Buy | 24.41 |
| Jones Trading | 31 Oct 2024 | 36.00 (57.41%) | Buy | 27.85 |
| HC Wainwright & Co. | 01 Oct 2024 | 37.00 (61.78%) | Buy | 26.00 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 13 Nov 2024 | Announcement | Enliven Therapeutics Reports Third Quarter Financial Results and Provides a Business Update |
| 07 Nov 2024 | Announcement | Enliven Therapeutics to Present at the Jefferies London Healthcare Conference |
| 28 Sep 2024 | Announcement | Enliven Therapeutics Announces Positive Data Update from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |